AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Invivyd Inc. (IVVD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.96

-0.15 (-7.11%)

At close: Feb 06, 2025, 3:59 PM

2.16

10.20%

After-hours Feb 06, 2025, 07:59 PM EST

undefined% (undefined)

Bid	2.16
Market Cap	234.46M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.95
PE Ratio (ttm)	-1.01
Forward PE	n/a
Analyst	Buy

Ask	2.17
Volume	72,734,799
Avg. Volume (20D)	11,446,090
Open	2.54
Previous Close	2.11
Day's Range	1.89 - 2.74
52-Week Range	0.35 - 5.10
Beta	undefined

About IVVD

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with A...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 6, 2021

Employees 94

Stock Exchange NASDAQ

Ticker Symbol IVVD

Website https://adagiotx.com

Analyst Forecast

According to 5 analyst ratings, the average rating for IVVD stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 359.16% from the latest price.

Buy 80.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Invivyd Inc. is scheduled to release its earnings on Mar 27, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 days ago

+17.92%

Invivyd shares are trading higher. HC Wainwright &... Unlock content with Pro Subscription

3 days ago

+196.34%

Invivyd shares are trading higher after the company provided preliminary Q4 PEMGARDA net product revenue results.

News

1 day ago · seekingalpha.com

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue i...

2 months ago · seekingalpha.com

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:18 AM ET Invivyd, Inc. (NASDAQ:IVVD ) Q3 2024 Earnings Conference Call November 14, 2024, 08:30 AM ET Company Participants Marc Elia - Chairperson, Board of Directo...

2 months ago · zacks.com

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.36 per share a year ago.